These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

150 related items for PubMed ID: 19416001

  • 21. Cutaneous toxicities of the multikinase inhibitors sorafenib and sunitinib.
    McLellan B, Kerr H.
    Dermatol Ther; 2011; 24(4):396-400. PubMed ID: 21910797
    [Abstract] [Full Text] [Related]

  • 22. Review: thyroid function abnormalities in patients receiving VEGF-targeted therapy.
    Rini BI.
    Clin Adv Hematol Oncol; 2011 Apr; 9(4):337-8. PubMed ID: 21558996
    [No Abstract] [Full Text] [Related]

  • 23. Can sorafenib cause hypothyroidism?
    Robinson SI, Hobday TJ, Sathananthan A, Morris JC, McWilliams RR.
    J Chemother; 2007 Jun; 19(3):352-3. PubMed ID: 17594936
    [No Abstract] [Full Text] [Related]

  • 24. Severe toxicity caused by sorafenib in hepatocellular carcinoma match the data from renal cell carcinoma.
    Lamarca A, Feliu J, Barriuso J.
    Br J Cancer; 2012 Mar 13; 106(6):1246. PubMed ID: 22294185
    [No Abstract] [Full Text] [Related]

  • 25. Sorafenib: muscle wasting.
    Prescrire Int; 2011 Dec 13; 20(122):296-7. PubMed ID: 22216546
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. [Medical treatment of metastatic renal cell carcinoma after the approval and market entry of multitargeted tyrosine kinase inhibitors in Germany].
    Bolenz C, Trojan L, Honeck P, Schöppler G, Herrmann E, Alken P, Michel MS, Häcker A.
    Aktuelle Urol; 2009 Jan 13; 40(1):31-6. PubMed ID: 19177319
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. High frequency of intracerebral hemorrhage in metastatic renal carcinoma patients with brain metastases treated with tyrosine kinase inhibitors targeting the vascular endothelial growth factor receptor.
    Pouessel D, Culine S.
    Eur Urol; 2008 Feb 13; 53(2):376-81. PubMed ID: 17825982
    [Abstract] [Full Text] [Related]

  • 32. Reader seeks clarification on hand-foot skin reaction.
    Clark M.
    Clin J Oncol Nurs; 2008 Jun 13; 12(3):395; author reply 395. PubMed ID: 18564457
    [No Abstract] [Full Text] [Related]

  • 33. Multitargeted agents for therapeutically challenging tumor: an introduction for oncology nurses.
    King CR.
    ONS News; 2006 Jun 13; 21(8 Suppl):57-8. PubMed ID: 16925154
    [No Abstract] [Full Text] [Related]

  • 34. Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials.
    Je Y, Schutz FA, Choueiri TK.
    Lancet Oncol; 2009 Oct 13; 10(10):967-74. PubMed ID: 19767240
    [Abstract] [Full Text] [Related]

  • 35. Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma.
    Schmidinger M, Zielinski CC, Vogl UM, Bojic A, Bojic M, Schukro C, Ruhsam M, Hejna M, Schmidinger H.
    J Clin Oncol; 2008 Nov 10; 26(32):5204-12. PubMed ID: 18838713
    [Abstract] [Full Text] [Related]

  • 36. [New drugs; sunitinib and sorafenib].
    Bellersen L.
    Ned Tijdschr Geneeskd; 2008 Feb 23; 152(8):469-70; author reply 470. PubMed ID: 18363211
    [No Abstract] [Full Text] [Related]

  • 37. [New drugs; sunitinib and sorafenib].
    van Bronswijk H, Dubois EA, Osanto S, Cohen AF.
    Ned Tijdschr Geneeskd; 2007 Dec 29; 151(52):2888-90. PubMed ID: 18257434
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Acute hepatitis in a patient with cirrhosis and hepatocellular carcinoma treated with sorafenib.
    Llanos L, Bellot P, Zapater P, Pérez-Mateo M, Such J.
    Am J Gastroenterol; 2009 Jan 29; 104(1):257-8. PubMed ID: 19098892
    [No Abstract] [Full Text] [Related]

  • 40. Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials.
    Choueiri TK, Schutz FA, Je Y, Rosenberg JE, Bellmunt J.
    J Clin Oncol; 2010 May 01; 28(13):2280-5. PubMed ID: 20351323
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.